China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
23.7
38.93
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
China Resources Boya Bio pharmaceutical Group Co Ltd
Net Income (Common)
China Resources Boya Bio pharmaceutical Group Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
|
Net Income (Common)
ÂĄ186.1m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
7%
|
||
Beigene Ltd
HKEX:6160
|
Net Income (Common)
-ÂĄ6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Net Income (Common)
ÂĄ2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Income (Common)
ÂĄ1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Net Income (Common)
ÂĄ1.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Net Income (Common)
ÂĄ3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
12%
|
CAGR 10-Years
39%
|
China Resources Boya Bio pharmaceutical Group Co Ltd
Glance View
Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. The company is headquartered in Fuzhou, Jiangxi and currently employs 1,652 full-time employees. The company went IPO on 2012-03-08. The firm's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The firm's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The firm also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The firm distributes its products mainly in domestic market.
See Also
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Net Income (Common)?
Net Income (Common)
186.1m
CNY
Based on the financial report for Sep 30, 2024, China Resources Boya Bio pharmaceutical Group Co Ltd's Net Income (Common) amounts to 186.1m CNY.
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
7%
Over the last year, the Net Income (Common) growth was -61%. The average annual Net Income (Common) growth rates for China Resources Boya Bio pharmaceutical Group Co Ltd have been -20% over the past three years , -18% over the past five years , and 7% over the past ten years .